NASDAQ · MBRX
Healthcare · Biotechnology
$0.59
Down-$0.00 (-0.10%)
Updated Aug 21, 2026, 7:45 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MBRX closed at $0.59 after 21 trading sessions, down 71.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $0.58 | $0.6361 | $0.55 | $0.5906 | 1.07M |
| Aug 19, 2026 | $0.6057 | $0.61 | $0.57 | $0.572 | 663.13K |
| Aug 18, 2026 | $0.60 | $0.66 | $0.59 | $0.6101 | 657.98K |
| Aug 17, 2026 | $0.6382 | $0.665 | $0.56 | $0.607 | 874.15K |
| Aug 14, 2026 | $0.60 | $0.64 | $0.58 | $0.6122 | 1.54M |
| Aug 13, 2026 | $0.5355 | $0.5841 | $0.525 | $0.5713 | 1.33M |
| Aug 12, 2026 | $0.4498 | $0.5339 | $0.43 | $0.5222 | 1.27M |
| Aug 11, 2026 | $0.43 | $0.46 | $0.41 | $0.445 | 994.72K |
| Aug 10, 2026 | $0.4198 | $0.46 | $0.4015 | $0.4304 | 1.56M |
| Aug 7, 2026 | $0.386 | $0.415 | $0.3805 | $0.4095 | 1M |
| Aug 6, 2026 | $0.40 | $0.418 | $0.3454 | $0.385 | 2.16M |
| Aug 5, 2026 | $0.41 | $0.439 | $0.3801 | $0.39 | 1.58M |
| Aug 4, 2026 | $0.439 | $0.439 | $0.38 | $0.4094 | 2.28M |
| Aug 3, 2026 | $0.37 | $0.45 | $0.1614 | $0.425 | 8.76M |
| Jul 31, 2026 | $0.8801 | $1.069 | $0.3123 | $0.40 | 19.31M |
| Jul 30, 2026 | $1.34 | $1.34 | $1.01 | $1.02 | 1.59M |
| Jul 29, 2026 | $2.13 | $2.16 | $1.33 | $1.36 | 1.71M |
| Jul 28, 2026 | $2.15 | $2.21 | $2.14 | $2.19 | 106.59K |
| Jul 27, 2026 | $2.14 | $2.26 | $2.09 | $2.19 | 110.27K |
| Jul 24, 2026 | $2.12 | $2.13 | $2.07 | $2.12 | 44.49K |
| Jul 23, 2026 | $2.08 | $2.12 | $2.04 | $2.08 | 36.15K |
The latest Smart Investors Daily articles mentioning MBRX.
MBRX research
Company profile and research snapshot.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 11, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 10, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 27, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Benzinga · Aug 3, 2026
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics (NASDAQ:RNAZ)
ChartMill · Jul 31, 2026
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
ChartMill · Jul 31, 2026
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MBRX.
